Title
Category
Credits
Event date
Cost
Archived NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
  • Non-Hodgkin's Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
$0.00
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.